Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season - Takeaways - MDSpire

Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season

  • By

  • Hannah Bahakel

  • Andrew J Spieker

  • Haya Hayek

  • Jennifer E Schuster

  • Lubna Hamdan

  • Daniel E Dulek

  • Carrie L Kitko

  • Tess Stopczynski

  • Einas Batarseh

  • Zaid Haddadin

  • Laura S Stewart

  • Anna Stahl

  • Molly Potter

  • Herdi Rahman

  • Justin Amarin

  • Spyros A Kalams

  • Claire E Bocchini

  • Elizabeth A Moulton

  • Susan E Coffin

  • Monica I Ardura

  • Rachel L Wattier

  • Gabriela Maron

  • Michael Grimley

  • Grant Paulsen

  • Christopher J Harrison

  • Jason Freedman

  • Paul A Carpenter

  • Janet A Englund

  • Flor M Munoz

  • Lara Danziger-Isakov

  • Natasha Halasa

  • for the Pediatric HCT Flu Study

  • Rakesh Goyal

  • Rendie McHenry

  • Margaret Bender

  • Shari Barto

  • Michael Russo

  • Lauren Shoemaker

  • Kenny Truong

  • Christopher Dvorak

  • Kim J Allison

  • Swati Naik

  • Christopher Williams

  • Samantha Blum

  • Kirsten Lacombe

  • Hannah Smith

  • September 16, 2024

  • 0 min

Share

  • 1

    Pediatric hematopoietic cell transplant recipients are at high risk for severe influenza-related morbidity and mortality.

  • 2

    High-dose trivalent influenza vaccine (HD-TIV) was shown to be more immunogenic than standard-dose quadrivalent influenza vaccine (SD-QIV) in a prior study.

  • 3

    In the subsequent influenza season, a single dose of either HD-TIV or SD-QIV was more immunogenic than two doses of the same formulation from the previous year.

  • 4

    Both HD-TIV and SD-QIV had similar rates of injection site and systemic reactions, indicating comparable safety profiles.

  • 5

    The findings suggest that one dose of influenza vaccine may be sufficient for pediatric HCT recipients after a two-dose schedule in the prior year.

Original Source(s)

Immunogenicity and Reactogenicity of High- or Standard-Dose Influenza Vaccine in a Second Consecutive Influenza Season

  • by Hannah Bahakel, Andrew J Spieker, Haya Hayek, Jennifer E Schuster, Lubna Hamdan, Daniel E Dulek, Carrie L Kitko, Tess Stopczynski, Einas Batarseh, Zaid Haddadin, Laura S Stewart, Anna Stahl, Molly Potter, Herdi Rahman, Justin Amarin, Spyros A Kalams, Claire E Bocchini, Elizabeth A Moulton, Susan E Coffin, Monica I Ardura, Rachel L Wattier, Gabriela Maron, Michael Grimley, Grant Paulsen, Christopher J Harrison, Jason Freedman, Paul A Carpenter, Janet A Englund, Flor M Munoz, Lara Danziger-Isakov, Natasha Halasa, for the Pediatric HCT Flu Study, Rakesh Goyal, Rendie McHenry, Margaret Bender, Shari Barto, Michael Russo, Lauren Shoemaker, Kenny Truong, Christopher Dvorak, Kim J Allison, Swati Naik, Christopher Williams, Samantha Blum, Kirsten Lacombe, Hannah Smith

  • September 16, 2024

Related Content

Redox-metabolic circuits as a central regulator of T cell-based immunotherapy

Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children

Senate Report Details Early Myocarditis Signals After COVID-19 Vaccination

Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.